Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hordenine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 4/20 | 0.64 |
| ▸ | ESR1 known ✓ | P03372 | 3/20 | 0.56 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.56 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.50 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.48 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.48 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.47 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.47 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.47 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.47 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.47 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.47 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hordenine SCHEMBL19896488 | 0.98 | HRH3 (0.67) | HRH3TAAR1ESR1ESR2BLM | |
| Hordenine SCHEMBL36798 | 0.98 | HRH3 (0.67) | HRH3TAAR1ESR1ESR2BLM | |
| Hordenine SCHEMBL11147428 | 0.95 | HRH3 (0.64) | HRH3TAAR1ESR1ESR2BLM | |
| Hordenine SCHEMBL28644842 | 0.93 | HRH3 (0.61) | HRH3TAAR1ESR1ESR2KDM4E | |
| Hordenine SCHEMBL18329336 | 0.88 | HRH3 (0.55) | HRH3TAAR1ESR1ESR2KDM4E | |
| Hordenine SCHEMBL6338584 | 0.88 | HRH3 (0.55) | HRH3TAAR1ESR1ESR2KDM4E | |
| SCHEMBL18762839 | 0.85 | HRH3 (0.84) | HRH3TAAR1KMT2ASIGMAR1ALDH1A1 | |
| Hordenine SCHEMBL18329338 | 0.85 | HRH3 (0.52) | HRH3TAAR1ESR1ESR2KDM4E | |
| SCHEMBL2475962 | 0.84 | ESR1 (0.55) | HRH3TAAR1ESR1ESR2KDM4E | |
| SCHEMBL28508133 | 0.83 | SIGMAR1 (0.62) | HRH3ESR1ESR2KDM4ECA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110632204-B | Method for detecting hordenine hydrochloride | 精晶药业股份有限公司 | 2022-02-25 | — | — | CN | claimed |
| CN-113620821-A | Preparation method of hordenine hydrochloride | 广汉市派瑞林科技有限责任公司 | 2021-11-09 | — | — | CN | claimed |
| CN-110632204-A | Method for detecting hordenine hydrochloride | 精晶药业股份有限公司 | 2019-12-31 | — | — | CN | claimed |
| US-20180055850-A1 | SYNERGISTIC NUTRACEUTICAL BEVERAGE FORMULATIONS PROVIDING ENHANCED THERMOGENESIS, MENTAL CLARITY, AND STAMINA WHILE MINIMIZING ADRENALINE AND DOPAMINE CONCENTRATION PERTURBATIONS ASSOCIATED WITH WITHDRAWAL | POWER SUPPLEMENTS, LLC | 2018-03-01 | — | — | US | claimed |
| US-20180055849-A1 | NUTRACEUTICAL CAPSULE AND TABLET FORMULATIONS PROVIDING ENHANCED MENTAL CLARITY, CONCENTRATION AND STAMINA WHILE MINIMIZING ADRENALINE AND DOPAMINE CONCENTRATION PERTURBATIONS ASSOCIATED WITH WITHDRAWAL | POWER SUPPLEMENTS, LLC | 2018-03-01 | — | — | US | claimed |
| CN-105331403-B | Fuel oil composite energy-saving additive and preparation method thereof | 无棣华信石油技术服务有限公司 | 2017-07-28 | — | — | CN | claimed |
| CN-106916073-A | A kind of synthetic method of hordenine hydrochloride | 上海巧坤化工科技有限公司 | 2017-07-04 | — | — | CN | claimed |
| WO-2025133198-A1 | ANTI-GREY HAIR CARE COMPOSITIONS | UNILEVER IP HOLDINGS B.V. (NL) | 2025-06-26 | — | — | WO | disclosed |
| EP-4308071-A1 | USE OF HORDENINE FOR TREATING CELLULAR SENESCENCE | Unilever IP Holdings B.V. (NL) | 2024-01-24 | — | — | EP | disclosed |
| US-20230270864-A1 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230027396-A1 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220401559-A1 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220062423-A1 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| CN-102316733-A | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INST MEDICAL W & E HALL | 2012-01-11 | — | — | CN | disclosed |
| EP-2373163-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-1625111-A4 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1625111-A2 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004093800-A2 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055849-A1 | NUTRACEUTICAL CAPSULE AND TABLET FORMULATIONS PROVIDING ENHANCED MENTAL CLARITY, CONCENTRATION AND STAMINA WHILE MINIMIZING ADRENALINE AND DOPAMINE CONCENTRATION PERTURBATIONS ASSOCIATED WITH WITHDRAWAL | SNCA, HIRA, HTR5A | HRH3 83/4885ESR1 4061/4885ESR2 4354/4885 |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | HRH3 3090/4885ESR1 415/4885ESR2 260/4885 |
| US-20180055850-A1 | SYNERGISTIC NUTRACEUTICAL BEVERAGE FORMULATIONS PROVIDING ENHANCED THERMOGENESIS, MENTAL CLARITY, AND STAMINA WHILE MINIMIZING ADRENALINE AND DOPAMINE CONCENTRATION PERTURBATIONS ASSOCIATED WITH WITHDRAWAL | COMT, PYGB, MAOB | HRH3 750/4885ESR1 4131/4885ESR2 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.